On September 27th 2018, we officially opened one of the largest agarose-based chromatography resin manufacturing facilities in the world. The site is dedicated solely to the manufacture of our Praesto® mAb purification portfolio and, to date, its construction has boosted local supply chains by £120 million whilst creating and safeguarding over 80 jobs in the UK.
Rt Hon Carwyn Jones AM, First Minister of Wales, and Steve Bates, Chief Executive Officer of the BioIndustry Association, officially opened the state-of-the-art facility with an inauguration ceremony attended by employees, valued partners and customers alike. A great day for all, and a proud moment in the history of Purolite.
Since the very beginning (1981), we have found success by identifying our customers’ pain-points and working smarter, faster and harder than our competitors to deliver the best answer to those problems. As a solutions company, that’s what Purolite has always done, and what we will always continue to do. With that in mind, one year on from the opening ceremony, it’s important to reflect on how the facility has changed us as a company, how it’s affected the market for agarose-based resins, and, most importantly, how our ethos and activities have resonated with our customer base in that time.
The Praesto® line was introduced several years ago, with the overarching goal of supplying higher-performing yet, for the first time, cost-efficient agarose chromatography resins, ultimately reducing the end-user cost of biologics. To aid us in achieving that goal, we needed to go out into the industry and gain as much customer feedback and insight as possible. So that’s what we did. Throughout the course of many conversations with people from all corners of the world, we noticed one issue underpinning several sources of frustration in the market - there was only one viable supplier for process-scale volumes of agarose chromatography resins.